Thus, the observed increase in IL-22 production coupled with decreased IL-17A and TNFα with SR3335 highlight the benefits of targeting RORα in chronic inflammatory diseases like IBD where such actions would prove beneficial to patients. Here, IL17A is linked to inflammatory bowel disease.